Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer

Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )
30 Jun 2022

War in Ukraine: Global cancer aid to support refugees

Dr Horia Vulpe , Dr Ruslan Baltaga
War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )
21 Jun 2022

War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis

Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance
War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )
21 Jun 2022

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity

Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )
13 Jun 2022

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )
13 Jun 2022

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA
Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )
13 Jun 2022

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )
13 Jun 2022

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022